Geneva researchers are repurposing existing drugs for rare diseases, offering new hope where options are scarce.
Postdoctoral fellow Jelena Gajić who works in Katanaev's lab is working with the ASNSD patient association to repurpose drugs for a rare, neurometabolic disease.
SWI Swissinfo
Researchers at the University of Geneva are scouring libraries of approved drugs in search of new treatments for rare diseases – with some success. The approach is now gaining traction globally as pharmaceutical companies’ interest in rare disease drug development wanes.
This content was published on
July 6, 2026 - 09:00
A Better Approach to Screening for Existing Drugs that Slow Aging
Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable
Scientists uncover 'mix and match' mechanism for creating new cancer-fighting drugs
Anthropic targets drug discovery for neglected diseases with Claude Science initiative
El plan de Anthropic: usar IA para encontrar medicamentos de enfermedades desatendidas
When David Fajgenbaum and his colleagues launched the drug repurposing non-profit Every Cure, they chose a path that challenged…
Supported by the EPFL Ignition Grant, three innovative projects, PolyDefine, Juturna Bio, and SwissIonics, are tackling some of…
Drug companies are betting AI can fix the slow, expensive process of testing new drugs in humans.
The partnership will enable Novo to better use AI to analyze complex datasets, and identify promising new drugs.
How Novartis and EPFL built a long-term collaboration grounded in structure and shared ambition.
Novartis eyes Alzheimer's and Parkinson's as it looks to expand the AOC platform acquired in its $12 billion Avidity Biosciences…
